DFTX Definium Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Definium Therapeutics Inc reported revenue of n/a, net income of −$159M and diluted EPS of −$1.44; for the fiscal year ended December 2025 revenue was n/a.
DFTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$166M, net income −$184M (margin n/a), EPS −$2.06
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$104M, net income −$109M (margin n/a), EPS −$1.54
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$93.9M, net income −$95.7M (margin n/a), EPS −$2.44
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$66.3M, net income −$56.8M (margin n/a), EPS −$1.84
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$93.9M, net income −$93.0M (margin n/a), EPS −$3.40
DFTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$159M, EPS −$1.44
- Quarter ended Mar 31, 2026: revenue n/a, net income −$77.1M, EPS −$0.71
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$50.4M, EPS −$0.43
- Quarter ended Sep 30, 2025: revenue n/a, net income −$67.3M, EPS −$0.78
- Quarter ended Jun 30, 2025: revenue n/a, net income −$42.7M, EPS −$0.50
- Quarter ended Mar 31, 2025: revenue n/a, net income −$23.3M, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$34.7M, EPS $0.13
- Quarter ended Sep 30, 2024: revenue n/a, net income −$13.7M, EPS −$0.27
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.85M, EPS −$0.26
- Quarter ended Mar 31, 2024: revenue n/a, net income −$54.4M, EPS −$1.14
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$23.9M, EPS −$0.58
- Quarter ended Sep 30, 2023: revenue n/a, net income −$17.9M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$29.1M, EPS −$0.76
- Quarter ended Mar 31, 2023: revenue n/a, net income −$24.8M, EPS −$0.65
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$4.90M, EPS −$0.02
- Quarter ended Sep 30, 2022: revenue n/a, net income −$16.5M, EPS −$0.56
- Quarter ended Jun 30, 2022: revenue n/a, net income −$17.0M, EPS −$0.60
- Quarter ended Mar 31, 2022: revenue n/a, net income −$18.5M, EPS −$0.66
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS −$2.64
- Quarter ended Sep 30, 2021: revenue n/a, net income −$17.2M, EPS −$0.61
DFTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$132M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$79.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$64.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$50.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$45.8M, share buybacks n/a
DFTX balance sheet
- Jun 30, 2026: cash $655M, total assets $1.11B, total liabilities $194M, shareholders' equity $919M, long-term debt $36.5M
- Mar 31, 2026: cash $263M, total assets $401M, total liabilities $122M, shareholders' equity $279M, long-term debt $40.8M
- Dec 31, 2025: cash $258M, total assets $440M, total liabilities $108M, shareholders' equity $332M, long-term debt $40.6M
- Sep 30, 2025: cash $20.0M, total assets $237M, total liabilities $106M, shareholders' equity $131M, long-term debt $40.4M
- Jun 30, 2025: cash $33.4M, total assets $265M, total liabilities $79.7M, shareholders' equity $185M, long-term debt $41.2M
- Mar 31, 2025: cash $82.9M, total assets $275M, total liabilities $52.5M, shareholders' equity $223M, long-term debt $22.0M
- Dec 31, 2024: cash $274M, total assets $302M, total liabilities $60.7M, shareholders' equity $241M, long-term debt $21.9M
- Sep 30, 2024: cash $295M, total assets $320M, total liabilities $57.6M, shareholders' equity $262M, long-term debt $24.3M
Is DFTX profitable?
No. Definium Therapeutics Inc lost $354M over the last four quarters.
What is DFTX's EPS?
Diluted earnings per share over the last four quarters were −$3.36; −$1.44 in the latest quarter.